Daily ReportOct 6, 2026
Anesthesiology, October 6 edition
We read 36 papers and selected 3.
Summary
The three most impactful papers addressed individualized perioperative decision-making through digital-twin-assisted consent, dual antiglutamate therapy for post-cardiac-arrest super-refractory status epilepticus, and adaptive closed-loop anesthetic delivery. Together, they combine randomized clinical evidence, multicenter comparative data, and translational engineering to advance patient-specific anesthetic and critical-care management.
Research Themes
- Personalized perioperative risk communication using digital twins
- Mechanism-based treatment of post-cardiac-arrest super-refractory status epilepticus
- Adaptive closed-loop control for precision anesthetic dosing
Selected Articles
1. Digital Twin-Assisted Risk Disclosure in Adults Undergoing Elective Bronchoscopy: Multicenter Randomized Controlled Trial.
In this multicenter randomized trial, 122 adults undergoing elective bronchoscopy were assigned to conventional consent or consent supported by a patient-specific digital-twin visualization derived from computed tomography. Digital-twin-assisted disclosure produced a greater reduction in anxiety and a modest improvement in satisfaction, although participants and physicians were not blinded and workflow and cost implications remain uncertain.
Impact: This study provides randomized evidence for a novel, patient-specific approach to informed consent that extends digital-twin technology from procedural training into clinical risk communication. It directly targets a common perioperative problem—anxiety—while preserving physician-led explanation.
Clinical Implications: Patient-specific airway and lesion visualization may be used as an adjunct to physician-led consent for bronchoscopy, particularly for patients who have difficulty understanding anatomical or procedural risks. Implementation should await assessment of consultation time, infrastructure requirements, accessibility, cost-effectiveness, and effects on objective decision quality.
Key Findings
- The multicenter trial randomized and analyzed 122 adults, with 61 participants in each group.
- Digital-twin-assisted disclosure reduced anxiety more than conventional disclosure on the visual analog scale, with a group-by-time coefficient of -15.89.
- Postbronchoscopy satisfaction improved modestly with digital-twin-assisted disclosure, but the intervention was not blinded and objective clinical benefits were not established.
Methodological Strengths
- Multicenter parallel-group randomized controlled design with prespecified anxiety and satisfaction outcomes.
- The intervention used each participant's computed tomography-derived anatomy rather than generic educational images.
Limitations
- Participants and physicians were not blinded, creating potential expectancy and reporting bias for subjective outcomes.
- The study did not establish effects on objective comprehension, procedural outcomes, consultation time, cost-effectiveness, or equity of access.
Future Directions: Future studies should compare time-matched consent workflows, measure objective comprehension and decisional quality, evaluate cost-effectiveness, and test implementation in highly anxious, low-literacy, and resource-limited populations. Pragmatic trials should determine whether the technology improves consent quality without delaying procedural care.
BACKGROUND: Risk disclosure before bronchoscopy should provide sufficient information for informed consent, but detailed text-based risk disclosure may increase procedural anxiety. Patient-specific visualization with a digital twin-based bronchoscopy simulator may help patients understand bronchoscopy and its risks in a more individualized manner. OBJECTIVE: This study evaluated whether digital twin-assisted risk disclosure reduces prebronchoscopy anxiety and improves postbronchoscopy satisfaction compared with conventional risk disclosure in adults scheduled for elective bronchoscopy.
2. Adaptive feedback control for the high-precision management of in-tissue drug concentrations.
The investigators developed an adaptive closed-loop controller that estimates subject-specific pharmacokinetics from real-time drug-concentration measurements and continuously updates dosing during infusion. In live rats, the system achieved predefined ventricular procaine concentrations within 20–30 minutes and maintained them with 5%-12% root-mean-squared deviation despite transport delays and physiological variation.
Impact: This work offers a mechanistic and engineering solution to a central limitation of anesthetic dosing: population pharmacokinetic models cannot fully account for rapid interindividual and intraindividual variation. Real-time individualized control could form the basis of safer automated drug delivery, although translation beyond rats remains unproven.
Clinical Implications: The platform could eventually enable closed-loop control of anesthetics or other narrow-therapeutic-index drugs using direct concentration feedback. Before human use, studies must address sensor reliability, infection and implantation risks, latency, failure detection, human pharmacokinetic complexity, and safe manual override procedures.
Key Findings
- The controller estimated individual pharmacokinetics during the initial infusion and continuously updated the model as physiology changed.
- In live rats, predefined ventricular procaine concentrations were reached within 20–30 minutes.
- Concentration maintenance achieved 5%-12% root-mean-squared deviation, including sensor noise, despite intracranial transport delays.
Methodological Strengths
- The controller was individualized from real-time concentration data rather than relying solely on population pharmacokinetic parameters.
- The system was tested in vivo in a challenging compartment with delayed drug transport and changing physiology.
Limitations
- The evidence was generated in live rats using procaine and does not establish safety or efficacy in humans.
- Sensor noise, implantation requirements, model failure, and long-term stability may limit clinical translation.
Future Directions: Further work should validate the controller across anesthetic agents, dosing routes, species, and clinically relevant physiological disturbances. Safety-focused studies should incorporate redundant sensing, anomaly detection, fail-safe dosing limits, and clinician override, followed by large-animal pharmacology and carefully monitored first-in-human studies.
The recent availability of a technology providing real-time, seconds-resolved in vivo drug concentration measurements has opened the door to performing fully autonomous, closed-loop feedback control over drug dosing. The controllers employed in prior demonstrations of such dosing, however, were designed and optimized using population-based pharmacokinetic models. In the face of individual pharmacokinetic variation (between subjects or even within a single subject over time as their physiology varies), these controllers must be set rather conservatively so as to avoid potentially dangerous overshooting.
3. Dual Antiglutamate Therapy in Super-Refractory Status Epilepticus After Cardiac Arrest (SUPER-CAT Study).
This multicenter cohort study compared ketamine plus perampanel, providing combined AMPA and NMDA receptor blockade, with other antiseizure and anesthetic regimens in carefully selected patients with postanoxic super-refractory status epilepticus. Among 95 eligible patients, dual antiglutamate therapy was associated with higher status epilepticus resolution than other treatments, 84% versus 49%, with the study registered prospectively.
Impact: The study challenges therapeutic nihilism after cardiac arrest by identifying a potentially treatable subgroup with preserved prognostic markers and demonstrating a large association between mechanistically targeted therapy and seizure resolution. It may influence neurocritical-care practice, but nonrandomized treatment allocation and selection criteria limit causal interpretation.
Clinical Implications: In selected post-cardiac-arrest patients without unfavorable multimodal prognostic indicators, combined ketamine and perampanel may be considered as a rescue strategy for super-refractory status epilepticus in specialized neurocritical-care settings. It should not yet be regarded as standard therapy; prospective comparative trials are needed.
Key Findings
- Among 1,352 post-cardiac-arrest intensive care patients, 95 met the eligibility criteria; 43 received dual antiglutamate therapy, 41 received other regimens, and 11 received a single antiglutamate agent.
- Status epilepticus resolution occurred in 84% of the dual-therapy group versus 49% of the other-treatment group, with an odds ratio of 5.4.
- Eligibility required preserved bilateral N20 cortical responses, intact pupillary reflexes, and absence of generalized periodic discharges, defining a selected subgroup without unfavorable prognostic indicators.
Methodological Strengths
- The multicenter design and explicit multimodal prognostic inclusion criteria improved clinical phenotyping and reduced inappropriate inclusion of patients with established unfavorable prognosis.
- The treatment protocol was mechanistically coherent, combining AMPA receptor blockade with NMDA receptor blockade, and the study had ClinicalTrials.gov registration NCT05756621.
Limitations
- The cohort was nonrandomized, so treatment selection, center effects, and residual confounding may explain part of the observed association.
- The study included a highly selected subgroup, limiting generalizability to patients with absent N20 responses, abnormal pupillary reflexes, or generalized periodic discharges.
Future Directions: Randomized or carefully controlled prospective studies should compare dual antiglutamate therapy with standardized contemporary care, evaluate neurologic function and quality of survival beyond seizure termination, and define optimal dosing and treatment duration. Biomarker-guided studies may identify which postanoxic patients are most likely to benefit.
BACKGROUND AND OBJECTIVES: The SUPER-refractory status epilepticus (SE) after Cardiac Arrest Treatment (SUPER-CAT) study evaluated the efficacy and safety of dual antiglutamate therapy (combined AMPA and NMDA receptor blockade) in patients with super-refractory SE (SRSE) after cardiac arrest and without unfavorable prognostic indicators. METHODS: Multicenter cohort study including patients with postanoxic SRSE meeting the following criteria: bilaterally preserved N20 cortical responses, intact pupillary reflexes, and absence of generalized periodic discharges.